While COVID-19 is still a threat, concerns about possible side effects may be keeping patients from getting the updated vaccine1,2
For representation purposes only. Actual size, packaging, and appearance may differ.
When it comes to vaccination, patient surveys are showing some interesting trends
A survey by the National Foundation for Infectious Diseases (NFID) found that many adults underestimate the seriousness of respiratory diseases, such as COVID-191
The survey also found that:
Only 40% of US adults plan to get an updated COVID-19 vaccine1*
Nearly half of people who do not plan to get vaccinated for COVID-19 expressed concern about possible side effects1*
*Data from a survey commissioned by the NFID in August 2023 to better understand beliefs about flu, COVID-19, respiratory syncytial virus (RSV), and pneumococcal disease, as well as attitudes and practices around vaccination in adults aged 18 years and older in the United States. A total of 1,000 complete responses were received, representing the 50 states and the District of Columbia.1
Our survey findings suggest that offering a protein-based COVID-19 vaccine may help you get more patients vaccinated4
When asked if they would prefer a protein-based COVID-19 vaccine over an mRNA option as part of a Novavax survey conducted in February 2024:
of individuals said they were open to receiving a protein-based vaccine4*
individuals preferred a protein-based vaccine much more than an mRNA option (21%)4*
Your patients may prefer an option built on trusted technology that has been used for decades in common vaccines, including some for HPV, influenza, and hepatitis B5,6
HPV=human papillomavirus.
*As part of a Novavax-sponsored survey conducted in February 2024, US vaccine adopters (defined as consumers who were previously vaccinated for COVID-19) were asked to what degree they would prefer a protein-based COVID-19 vaccine vs mRNA vaccines currently being offered, such as those from Pfizer-BioNTech and Moderna. Participants were given 3 responses to choose from: “prefer much more,” “prefer much less,” and “about the same.” Sample size was 1,000 participants, 18 years of age or older.4
†Data from the National Immunization Survey Adult COVID Module (NIS-ACM), which was conducted between April and September of 2021 in the United States, were analyzed by the Centers for Disease Control and Prevention to examine the prevalence of provider recommendations for COVID-19 vaccination and their association with COVID-19 vaccination coverage and attitude in adults aged 18 years and older.3
References: 1. National Foundation for Infectious Diseases. Attitudes about influenza, COVID-19, respiratory syncytial virus, and pneumococcal disease. https://www.nfid.org/resource/2023-national-survey-attitudes-about-influenza-covid-19-respiratory-syncytial-virus-and-pneumococcal-disease. Published September 28, 2023. Accessed June 17, 2024. 2. Centers for Disease Control and Prevention. RESP-NET interactive dashboard. https://www.cdc.gov/resp-net/dashboard/index.html. Updated June 3, 2024. Accessed July 18, 2024. 3. Nguyen KH, Yankey D, et al. Report of health care provider recommendation for COVID-19 vaccination among adults, by recipient COVID-19 vaccination status and attitudes—United States, April–September 2021. MMWR Morb Mortal Wkly Rep. 2021;70(50):1723-1730. 4. Data on file. Novavax, Inc. 2024. 5. Novavax COVID-19 Vaccine, Adjuvanted (2024-2025 Formula) EUA Fact Sheet for Healthcare Providers. Novavax Inc.; September 2024. 6. Cid R, Bolívar J. Platforms for production of protein-based vaccines: from classical to next-generation strategies. Biomolecules. 2021;11(8):1072.